{"id":"W4382811670","doi":"10.1016/j.annonc.2023.04.487","title":"SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; Chugai Pharmaceutical; University of California, San Francisco; Genentech; Humanitas Research Hospital; Sirtex Medical; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas; Humanitas University; Ludwig-Maximilians-Universität München; Universidad de Navarra; Khon Kaen University; FibroGen; Astellas Pharma; Eisai; Kanazawa University; BeiGene; University of Ulsan; Pfizer; Incyte; Agios Pharmaceuticals; Ipsen; Clinical Trial Center, China Medical University Hospital; Parker Institute for Cancer Immunotherapy; Sanofi; Exelixis; Boston Scientific Corporation; Eli Lilly and Company; Chinese University of Hong Kong; Helsinn; EA Pharma Co., Ltd.; National Cancer Institute; Servier; Gilead Sciences; AstraZeneca; Kindai University","keywords":"Durvalumab; Tremelimumab; Medicine; Hepatocellular carcinoma; Oncology; Internal medicine; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004795406,0.0004989809,0.002104038,0.0005056963,0.0003299916,0.001438626,0.0006390556,0.0004522995,0.001490196],"category_scores_gemma":[0.002467062,0.0002565286,0.00162643,0.001132012,0.0002681004,0.0005784222,0.0006834226,0.001173134,0.0004411797],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001352807,"about_ca_system_score_gemma":0.001777047,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004011621,"about_ca_topic_score_gemma":0.01098643,"domain_scores_codex":[0.9991241,0.0003985834,0.0000687495,0.00005188481,0.0002239354,0.0001327768],"domain_scores_gemma":[0.9980872,0.0005571851,0.0004363429,0.000170314,0.0003868638,0.0003621688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1626608,0.002068805,0.2250015,0.00367099,0.02218626,0.0004711624,0.0007557451,0.008438838,0.009272055,0.001060604,0.05064588,0.5137673],"study_design_scores_gemma":[0.04724045,0.02550226,0.7773967,0.001092513,0.0227987,0.0009251488,0.0003837222,0.002417254,0.003915172,0.001322422,0.1168381,0.0001675083],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8716945,0.07083422,0.002189529,0.005811406,0.0009286008,0.001085949,0.03538544,0.0002154918,0.01185482],"genre_scores_gemma":[0.9178045,0.02460513,0.003209863,0.004700426,0.0007494005,0.001309904,0.04440024,0.0001100129,0.003110556],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004795406,"threshold_uncertainty_score":0.02536082,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2225889435793515,"score_gpt":0.3668007661172619,"score_spread":0.1442118225379104,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}